{"name":"Editas Medicine, Inc.","slug":"editas","ticker":"EDIT","exchange":"NASDAQ","domain":"editasmedicine.com","description":"Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.","hq":"Cambridge, MA","founded":0,"employees":"87","ceo":"Gilmore O\\","sector":"Biotech — Gene Editing","stockPrice":2.88,"stockChange":-0.02,"stockChangePercent":-0.69,"marketCap":"$282M","metrics":{"revenue":38693000,"revenueGrowth":-39.2,"grossMargin":-109.2,"rdSpend":0,"netIncome":-108954000,"cash":123648000,"dividendYield":0,"peRatio":-3.2,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Editas Medicine Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Editas Medicine reported its fourth quarter and full year 2023 financial results, with revenue of $24.4 million and a net loss of $143.6 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Editas Medicine Announces Collaboration with Pfizer to Develop Gene Editing Therapies","summary":"Editas Medicine announced a collaboration with Pfizer to develop gene editing therapies for various diseases, including sickle cell disease and beta-thalassemia.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"FDA Grants Fast Track Designation to EDIT-101 for the Treatment of LCA10","summary":"The FDA granted fast track designation to EDIT-101, Editas Medicine's lead product candidate, for the treatment of Leber congenital amaurosis 10 (LCA10).","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNNjBqUk04OThRVlZ2dFR4Z3VhRHdZdWpGYU5wMjdGN0hSV19OWGRhV2NfOF91MVJBVUVfeEFMSWJrbjJoR05sSFBXLWQwTmhsaHF5bWwxdmtGampINDl3M2x6WjNuOW9zNDdtWmJlSXRVSGE2Z0k3ZmV5LUNUWUZnaG5ha1FVLXBXWnQxQWJsNVVDVG9fMG00ZmRGUQ?oc=5","date":"2026-03-10","type":"earnings","source":"Finviz","summary":"EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y - Finviz","headline":"EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-01-23","type":"earnings","source":"simplywall.st","summary":"Individual investors who hold 55% of Editas Medicine, Inc. (NASDAQ:EDIT) gained 14%, institutions profited as well - simplywall.st","headline":"Individual investors who hold 55% of Editas Medicine, Inc. (NASDAQ:EDIT) gained 14%, institutions profited as well","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-13","type":"pipeline","source":"simplywall.st","summary":"Analysts Are Upgrading Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results - simplywall.st","headline":"Analysts Are Upgrading Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-05","type":"pipeline","source":"simplywall.st","summary":"Lacklustre Performance Is Driving Editas Medicine, Inc.'s (NASDAQ:EDIT) 29% Price Drop - simplywall.st","headline":"Lacklustre Performance Is Driving Editas Medicine, Inc.'s (NASDAQ:EDIT) 29% Price Drop","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPblZ2UUxpU3UxMi1ZamJHWEhOWnVpQVBManNQYmIwN0h0MTlKRmNab0RoYUVHaDRoWU9xSUtVNHB1MEN4MFhvRjRQMXFGd21keXFOSWlMOHdHYU9kR0hwTkNrd3diRDdPM29tOEpVUW5obElJVDZRN1FTN3dRS1BHZE81d3JBM2g0bUo5TlNoZ3ZpWTJKdlA5Tk9XZkh4aDdyazJlSktaSG9vakU?oc=5","date":"2025-07-30","type":"pipeline","source":"Seeking Alpha","summary":"Editas Medicine - Primed For An Unlikely Comeback? It's Not Impossible - Seeking Alpha","headline":"Editas Medicine - Primed For An Unlikely Comeback? It's Not Impossible","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNZzk2Z0IwaHo5OXRyRm43cWNac3hyVGhCWV85WU1pQVJTemVxSjhrQTVwb3lBYVlRTDY3RUVhU29MbEd2WnJVX2VqRXB3bVVoWlNlaHk2a21tLVBSLVBOZkczRUpaNzVNWi1nMFFwTUM3cTJLREFWSHAxSnlzbl8xX2hFQUVmbW1mTjBYVVZEdFgxVTdVY21r?oc=5","date":"2025-06-28","type":"deal","source":"The Motley Fool","summary":"Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? - The Motley Fool","headline":"Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOV214TU8zM0NBNFNONlM0Si1DaVpQLVNiN1JMMXBtN3hlTmk4ZUdRN3M3aVlpZ1RrQ0x2cUNKOXpEOVpGR1lvOXdETURwZDNnQkFObjRaVzRYX1ViZFZVRWE3U2QtWUIzNENkZ1RwYzV4Smcta3RiUXNySWEyQzRiS3JnSUMzenZ3bXhMYQ?oc=5","date":"2025-05-15","type":"pipeline","source":"Pharma Voice","summary":"A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory - Pharma Voice","headline":"A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPeldrSmN1eHZHY25SNHhtaXVTMHNnNVQ5WVVhcV83MTB2eUNPQU1EM1lFM3cwRTZiUlB3czJiTE9PTFBTeFFuUks4SmRMOHltcGdrZGpfSHowUXpyaTdkN2hsZ0FLSWFQY0YxcHFaY3JRaDdic0hxclFvbzhxUjVfb21XT0RrdUE?oc=5","date":"2024-12-13","type":"pipeline","source":"pharmaphorum","summary":"Editas axes two-thirds of its staff, including its CMO - pharmaphorum","headline":"Editas axes two-thirds of its staff, including its CMO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOMjJTS1ZPNTdFdzEwUVNsWThtZmpiQ0NBYVdlc2JES0stZkJqYm1DdTh1Sng2c1FacmktMjl5d2dRYVMzMFJCRlZCZThILThrQmFseXVTQlBTMUJQMldmWmkybTRKYXhqczlYMmNCaDVCQ0UtbFVBZ0dEN3ctZy13N21VTXZFSG8?oc=5","date":"2024-10-31","type":"pipeline","source":"Yahoo Finance","summary":"Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock? - Yahoo Finance","headline":"Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxObXBpYTN3cGlwNjMwMVpKVkwzNzY0RVNQc0JyWlpBTk1OS1gyMmRUM084SWZjN3ZBSnYydnU4cm9XdXA3Zi0xMkxnUTNwcDZCYXVLUnVQQjlJU05YQWFiTWt1VGhXVUZZY05POWZ3WnR5MDZmalNDX2ZuVWkxX2xNTHhwdjk0bUZzZFRFZG11WHZkazh6Rl9jSEpqeXVqQVgtZW9fcQ?oc=5","date":"2024-10-22","type":"deal","source":"BioPharma Dive","summary":"Editas, changing course again, looks to partner lead CRISPR therapy - BioPharma Dive","headline":"Editas, changing course again, looks to partner lead CRISPR therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOYmhEaTJQS3BwUVpKdUdUcHFsb1M0OHFpc1JrRWZybW5aSFFjQmZGRVZlZ1JDd1AyTWFIek9PeGlMdkNYSnA3ak1Kb2lJV2F0MmNzdzZNY0VfeUNOdVl1aFdWMlFMUmpfY1JobVk3dExPemxlekRWZXVaYnJkLWRxYUpISXNLbUtFdEtac0dMOU15RHVsQ19tRjFqT0oyajRiRkVSRzdn?oc=5","date":"2020-07-29","type":"deal","source":"Contract Pharma","summary":"Catalent Partners with Gene Editing Company Editas - Contract Pharma","headline":"Catalent Partners with Gene Editing Company Editas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNelJ0N1Jqb1FKYXlWY2ZVT1NoNlIwZGhJd3psTV8xcVY5U0JuNmpOV3FMUmdNSXpVWGdDTFNMc2tyZm9MYXYtT2ZtbXBxTFdKQWNvekZKcWViRjF5cS11MWgxZUZydktna2FvUjZwTlU1d3lURTFzQnlsXzhseGNfWWltN2FIdWNPN3M1d1hoYjVqX0F3bWRIOG9xU2tuUzVBLW16bjZxSjVOQUdlTEYtbzBqSDNXRUxnUWxHWGpB?oc=5","date":"2017-03-14","type":"pipeline","source":"Editas Medicine","summary":"Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases - Editas Medicine","headline":"Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines f","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["CRISPR Therapeutics AG (CRSP)","Intellia Therapeutics, Inc. (NTLA)","Beam Therapeutics Corp. (BEAM)"],"therapeuticFocus":["Gene Editing","Rare Diseases","Ophthalmology"],"financials":{"source":"yahoo_finance","revenue":40520000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":40520000},{"period":"2024-12-31","value":32314000},{"period":"2023-12-31","value":78123000},{"period":"2022-12-31","value":19712000}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":89953000,"rdSpendHistory":[{"period":"2025-12-31","value":89953000},{"period":"2024-12-31","value":199247000},{"period":"2023-12-31","value":177651000},{"period":"2022-12-31","value":174958000}],"sgaSpend":49903000,"operatingIncome":-99336000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-99336000},{"period":"2024-12-31","value":-238920000},{"period":"2023-12-31","value":-169181000},{"period":"2022-12-31","value":-225950000}],"netIncome":-160060000,"netIncomeHistory":[{"period":"2025-12-31","value":-160060000},{"period":"2024-12-31","value":-237093000},{"period":"2023-12-31","value":-153219000},{"period":"2022-12-31","value":-220432000}],"eps":-2.88,"epsHistory":[{"period":"2024-12-31","value":-2.88},{"period":"2023-12-31","value":-2.02},{"period":"2022-12-31","value":-3.21},{"period":"2021-12-31","value":-2.85}],"cash":146645000,"cashHistory":[{"period":"2025-12-31","value":146645000},{"period":"2024-12-31","value":131541000},{"period":"2023-12-31","value":123652000},{"period":"2022-12-31","value":141522000}],"totalAssets":186534000,"totalLiabilities":159246000,"totalDebt":18102000,"equity":27288000,"operatingCashflow":-165241000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-165241000},{"period":"2024-12-31","value":-210284000},{"period":"2023-12-31","value":-132178000},{"period":"2022-12-31","value":-177349000}],"capex":-607000,"capexHistory":[{"period":"2025-12-31","value":-607000},{"period":"2024-12-31","value":-8826000},{"period":"2023-12-31","value":-4719000},{"period":"2022-12-31","value":-4118000}],"freeCashflow":-165848000,"dividendsPaid":null,"buybacks":null,"employees":87,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":11353000,"ebit":-6084000,"ebitda":-5279000,"period":"2025-12-31","revenue":24741000,"epsBasic":-0.06,"netIncome":-5620000,"rdExpense":27404000,"epsDiluted":-0.06,"grossProfit":null,"operatingIncome":-14016000},{"sga":12316000,"ebit":-22718000,"ebitda":-21997000,"period":"2025-09-30","revenue":7543000,"epsBasic":-0.28,"netIncome":-25117000,"rdExpense":19775000,"epsDiluted":-0.28,"grossProfit":null,"operatingIncome":-24548000},{"sga":12859000,"ebit":-51215000,"ebitda":-49381000,"period":"2025-06-30","revenue":3578000,"epsBasic":-0.63,"netIncome":-53235000,"rdExpense":16181000,"epsDiluted":-0.63,"grossProfit":null,"operatingIncome":-25462000},{"sga":13375000,"ebit":-73872000,"ebitda":-71955000,"period":"2025-03-31","revenue":4658000,"epsBasic":-0.92,"netIncome":-76088000,"rdExpense":26593000,"epsDiluted":-0.92,"grossProfit":null,"operatingIncome":-35310000},{"sga":16354000,"ebit":-34361000,"ebitda":-32980000,"period":"2024-12-31","revenue":30604000,"epsBasic":-0.55,"netIncome":-45395000,"rdExpense":48611000,"epsDiluted":-0.55,"grossProfit":null,"operatingIncome":-34361000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":2.88,"previousClose":2.9,"fiftyTwoWeekHigh":4.54,"fiftyTwoWeekLow":1.34,"fiftyTwoWeekRange":"1.345 - 4.537","fiftyDayAverage":2.77,"twoHundredDayAverage":2.64,"beta":2.14,"enterpriseValue":177577216,"forwardPE":-3.2,"priceToBook":64,"priceToSales":7.29,"enterpriseToRevenue":4.59,"enterpriseToEbitda":-2.08,"pegRatio":0,"ebitda":-85186000,"ebitdaMargin":-220.2,"freeCashflow":-73816000,"operatingCashflow":-140503008,"totalDebt":17297000,"debtToEquity":392.4,"currentRatio":3.22,"returnOnAssets":-26.9,"returnOnEquity":-326.1,"analystRating":"2.1 - Buy","recommendationKey":"buy","numberOfAnalysts":9,"targetMeanPrice":5.78,"targetHighPrice":15,"targetLowPrice":1,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.3,"institutionHeldPercent":54.1,"sharesOutstanding":97906282,"floatShares":97636061,"sharesShort":10007345,"shortRatio":6.35,"shortPercentOfFloat":10.2,"epsTrailing":-1.14,"epsForward":-0.91,"revenuePerShare":0.42,"bookValue":0.04,"officers":[{"age":61,"name":"Dr. Gilmore  O'Neill M.D.","title":"President, CEO & Director"},{"age":39,"name":"Ms. Amy  Parison","title":"Senior VP & CFO"},{"age":68,"name":"Dr. Linda C. Burkly Ph.D.","title":"Executive VP & Chief Scientific Officer"},{"age":null,"name":"Dr. Feng  Zhang Ph.D.","title":"Co-Founder & Scientific Advisory Board Member"},{"age":71,"name":"Dr. George McDonald Church Ph.D.","title":"Co-Founder & Scientific Advisory Board Member"},{"age":null,"name":"Mr. Gregory  Whitehead","title":"Executive VP and Chief Technical & Quality Officer"},{"age":null,"name":"Mr. Damien  Grierson J.D.","title":"Senior VP, General Counsel & Corporate Secretary"},{"age":null,"name":"Mr. Tom  Love","title":"Vice President of People"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.editasmedicine.com","phone":"617 401 9000"}}